Oculis Holding AG (NASDAQ:OCS - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $18.70, but opened at $20.35. Oculis shares last traded at $20.41, with a volume of 64,061 shares traded.
Analyst Upgrades and Downgrades
Several research firms have weighed in on OCS. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Oculis in a report on Monday. Chardan Capital reissued a "buy" rating and issued a $28.00 price objective on shares of Oculis in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $28.80.
Read Our Latest Report on OCS
Oculis Trading Up 13.1 %
The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The company has a 50-day moving average price of $16.41 and a 200-day moving average price of $13.91.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Recommended Stories
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
